Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Oct 23 - Oct 28
The company filed for marketing approval of their semaglutide biosimilar for the treatment of T2D with the National Medical Products Administration (NMPA) in April 2024, and this is expected to amplify clinical development of semaglutide biosimilars from domestic manufacturers in the next two to three years
Dual therapy showed the greatest benefit, with a 39% reduction in cancer incidence (HR 0.61, 95% CI 0.570.65) and a 67% reduction in all-cause mortality (HR 0.33, 95% CI 0.320.35)
This not only helps reduce reliance on other diabetes medications but also lowers the risk of complications that come from unstable blood sugar
Bid farewell to excess weight and step into a world of elegance and vitality
Advanced conversion scenarios Some situations require more complex calculations than the standard formula
